At a glance
ClinicalIndex Comparison RecordN/ACompleted· 180 enrolled
Drug / intervention
PINPOINTdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
Novadaq Technologies ULC, now a part of Stryker·interventional·Posted Aug 6, 2014·Updated Mar 25, 2019
In Brief
A clinical study evaluating PINPOINT for Endometrial Cancer and 2 related conditions. Completed, enrolled 180 participants across 8 sites in 3 countries.
Detailed Summary
This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and cervical malignancies who are undergoing LN mapping.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Uterine Cancer, Cervical Cancer
CountriesCanada, Puerto Rico, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartDec 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedAug 6, 2014
Enrollment StartDec 1, 2015
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.9 years ago
Interventions
PINPOINTdevice
PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes